Drug news
REFLECTIONS B7391003 study, of biosimilar PF-06439535 versus Avastin (bevacizumab), met its primary objective for treatment of NSCLC.- Pfizer
Pfizer Inc. announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin.
The trial demonstrated equivalence in the primary endpoint of objective response rate (ORR) of PF-06439535 versus Avastin, taken in combination with carboplatin/paclitaxel, for the first line treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Comment: Avastin patents are estimated to expire in the US in July 2019 and in the EU in 2022.